Foghorn Therapeutics Inc. (FHTX) is a Biotechnology company in the Healthcare sector, currently trading at $4.85. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is FHTX = $12 (+140.6% upside).
Valuation: FHTX trades at a trailing Price-to-Earnings (P/E) of -4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.35.
Financials: revenue is $31M, +26.9%/yr average growth. Net income is $74M (loss), growing at +11.9%/yr. Net profit margin is -240.3% (negative). Gross margin is 89.2% (-10.7 pp trend).
Balance sheet: total debt is $41M with negative equity of -$109M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 2.73 (strong liquidity). Debt-to-assets is 20.8%. Total assets: $198M.
Analyst outlook: 8 / 9 analysts rate FHTX as buy (89%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 91/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).
